Home
ARMGO Pharma

ARMGO Pharma Market Share Analysis for May 2026

Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg dosing of ARM210 daily in patients with Ryanodine Receptor 1 Related Myopathies Provides first signs of clinical efficacy improving fatigue and proximal muscle strength in patients at 200 mg daily Corroborates allosteric mechanism of action of Rycal® ARM210 to restore […]

Industry: N/A

Domainarmgo.com

Year Founded2004

Employees51 - 200

Annual Revenue$15M - $25M

ARMGO Pharma

ARMGO Pharma (including company regionals)

armgo.com

See more website traffic and engagement information

ARMGO Pharma Revenue up to May 2026 is 15M - 25M

revenue generated by ARMGO Pharma top domains

ARMGO Pharma top domains revenue over 3 years

Revenue for ARMGO Pharma top domains

armgo.com15M - 25M

See more with Sales Intelligence

Total visits to ARMGO Pharma's top domains

Understand ARMGO Pharma market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ARMGO Pharma's top domains

Analyze ARMGO Pharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ARMGO Pharma's top domains

See how ARMGO Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ARMGO Pharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by ARMGO Pharma

These are the website technologies, by industry, used by ARMGO Pharma top domains

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Advertising (1)

DoubleClick

More Technologies

5

See all

News & Signals from ARMGO Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArmgo received financing of $35M in financing round on Dec 20th '21.ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders today announced that it has completed a $35 million financing led by Forbion.

NewsBelvedere leaves Armgo.Dr. Belvedere joins Forkhead from ARMGO Pharma, where he directed a chemistry discovery, development, and manufacturing program.